121 related articles for article (PubMed ID: 7539769)
1. Synergistic phosphorylation of platelet rap1B by SIN-1 and iloprost.
Grünberg B; Negrescu E; Siess W
Eur J Pharmacol; 1995 Feb; 288(3):329-33. PubMed ID: 7539769
[TBL] [Abstract][Full Text] [Related]
2. Platelet rap1B phosphorylation is a sensitive marker for the action of cyclic AMP- and cyclic GMP-increasing platelet inhibitors and vasodilators.
Grünberg B; Kruse HJ; Negrescu EV; Siess W
J Cardiovasc Pharmacol; 1995 Apr; 25(4):545-51. PubMed ID: 7596121
[TBL] [Abstract][Full Text] [Related]
3. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside.
Negrescu EV; Grünberg B; Kratzer MA; Lorenz R; Siess W
Cardiovasc Drugs Ther; 1995 Aug; 9(4):619-29. PubMed ID: 8547213
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide stimulates the phosphorylation of rap1b in human platelets and acts synergistically with iloprost.
Reep BR; Lapetina EG
Biochem Biophys Res Commun; 1996 Feb; 219(1):1-5. PubMed ID: 8619788
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
6. Effects of nitrovasodilators on platelet cyclic nucleotide levels in rabbit blood; role for cyclic AMP in synergistic inhibition of platelet function by SIN-1 and prostaglandin E1.
Bowen R; Haslam RJ
J Cardiovasc Pharmacol; 1991 Mar; 17(3):424-33. PubMed ID: 1711604
[TBL] [Abstract][Full Text] [Related]
7. Synergistic platelet antiaggregatory effects of the adenylate cyclase activator iloprost and the guanylate cyclase activating agent SIN-1 in vivo.
Spiecker M; Darius H; Meyer J
Thromb Res; 1993 Jun; 70(5):405-15. PubMed ID: 7690993
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of rap1B by protein kinase A is not involved in platelet inhibition by cyclic AMP.
Siess W; Grünberg B
Cell Signal; 1993 Mar; 5(2):209-14. PubMed ID: 7684600
[TBL] [Abstract][Full Text] [Related]
10. Synergistic phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphoprotein in intact human platelets in response to cGMP- and cAMP-elevating platelet inhibitors.
Nolte C; Eigenthaler M; Horstrup K; Hönig-Liedl P; Walter U
Biochem Pharmacol; 1994 Oct; 48(8):1569-75. PubMed ID: 7980622
[TBL] [Abstract][Full Text] [Related]
11. Organic nitrates and compounds that increase intraplatelet cyclic guanosine monophosphate (cGMP) levels enhance the antiaggregating effects of the stable prostacyclin analogue iloprost.
Anfossi G; Massucco P; Mularoni E; Cavalot F; Mattiello L; Trovati M
Prostaglandins Leukot Essent Fatty Acids; 1993 Nov; 49(5):839-45. PubMed ID: 7508131
[TBL] [Abstract][Full Text] [Related]
12. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin.
Russo I; Traversa M; Bonomo K; De Salve A; Mattiello L; Del Mese P; Doronzo G; Cavalot F; Trovati M; Anfossi G
Obesity (Silver Spring); 2010 Apr; 18(4):788-97. PubMed ID: 19834474
[TBL] [Abstract][Full Text] [Related]
13. Interaction between SIN-1 and prostacyclin in inhibiting platelet aggregation.
Bult H; Fret HR; Herman AG
J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S120-3. PubMed ID: 2484689
[TBL] [Abstract][Full Text] [Related]
14. Potential interactions between iloprost and SIN-1 on platelet aggregation and myocardial infarct size in vivo.
Aitchison KA; Coker SJ
Eur J Pharmacol; 1999 Jun; 374(1):59-69. PubMed ID: 10422641
[TBL] [Abstract][Full Text] [Related]
15. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
16. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity.
Anfossi G; Russo I; Massucco P; Mattiello L; Doronzo G; De Salve A; Trovati M
Eur J Clin Invest; 2004 Jul; 34(7):482-9. PubMed ID: 15255785
[TBL] [Abstract][Full Text] [Related]
17. Functional relationship between cyclic AMP-dependent protein phosphorylation and platelet inhibition.
Siess W; Grünberg B; Luber K
Adv Exp Med Biol; 1993; 344():229-35. PubMed ID: 7516112
[No Abstract] [Full Text] [Related]
18. Interaction between NO donors and iloprost in human vascular smooth muscle, platelets, and leukocytes.
Gryglewski RJ; Korbut R; Trabka-Janik E; Zembowicz A; Trybulec M
J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S124-8. PubMed ID: 2484690
[TBL] [Abstract][Full Text] [Related]
19. Vasodilator-Stimulated Phosphoprotein (VASP)-dependent and -independent pathways regulate thrombin-induced activation of Rap1b in platelets.
Benz PM; Laban H; Zink J; Günther L; Walter U; Gambaryan S; Dib K
Cell Commun Signal; 2016 Sep; 14(1):21. PubMed ID: 27620165
[TBL] [Abstract][Full Text] [Related]
20. Effects of nitric oxide and prostacyclin on deformability and aggregability of red blood cells of rats ex vivo and in vitro.
Starzyk D; Korbut R; Gryglewski RJ
J Physiol Pharmacol; 1999 Dec; 50(4):629-37. PubMed ID: 10639013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
